Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SightLine Partners has raised $107 million for a fund that will back late-stage medical-technology companies, the firm announced Thursday. The Minneapolis-based company won't invest in startups, but will shore up device makers that are struggling to raise the capital they need to get across the finish line. SightLine also is targeting investors in those firms, some of which are eager to sell their stakes in startups.
Help employers find you! Check out all the jobs and post your resume.
SightLine Partners has raised $107 million for a fund that will back late-stage medical-technology companies, the firm announced Thursday. The Minneapolis-based company won't invest in startups, but will shore up device makers that are struggling to raise the capital they need to get across the finish line. SightLine also is targeting investors in those firms, some of which are eager to sell their stakes in startups.
Help employers find you! Check out all the jobs and post your resume.
